Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | Not yet disclosed by govt.Likely | 24 | - |
| 2 | Schedule 2 | M.K.BROTHERSLikely | 1 | ₹4.9 L |
| 3 | Schedule 3 | SMPL LIFE SCIENCES PRIVATE LIMITEDLikely | 1 | ₹30,051 |
| 4 | Schedule 4 | Not yet disclosed by govt.Likely | 24 | - |
| 5 | Schedule 5 | SMPL LIFE SCIENCES PRIVATE LIMITEDLikely | 1 | ₹11,655 |
Tender Value
₹7.0 L
EMD Value
Exempted
Closing Date
18 Nov 2025, 8:00 pmClosed
Abiraterone 500 mg tab
Asciminib 40 mg tab
Sofosbuvir 400 mg and Velpatasvir 100 mg cap
Acalabrutinib 100 mg cap
Relugolix 120 mg tab
8499477
GEM/2025/B/6813320
Two Packet Bid
Abiraterone 500 mg tab
15 days
Gwalior, Madhya Pradesh
Item wise evaluation
BOQ
6 documents required · 6 mandatory
2 yrs
₹3 L
₹25 L
50%
Exempted
19 Nov 2025
4 Nov 2025
18 Nov 2025
| Item No | Item Title | Description | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|---|
| 1 | Abiraterone 500 mg tab | Cancer Medicines | 540 | No | GW ALIOR | 15 |
| 2 | Asciminib 40 mg tab | Cancer Medicines | 180 | No | GW ALIOR | 15 |
| 3 | Sofosbuvir 400 mg and Velpatasvir 100 mg cap | Cancer Medicines | 270 | No | GW ALIOR | 15 |
| 4 | Acalabrutinib 100 mg cap | Cancer Medicines | 180 | No | GW ALIOR | 15 |
| 5 | Relugolix 120 mg tab | Cancer Medicines | 90 | No | GW ALIOR | 15 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_8499477.pdf
GEM_BID
tech_2025-10-22-12-43-06_c7976be4f1ab97e0d29cb25b1619fc08.pdf
BOQ
boq_item_sample_file_2025-10-22-12-43-06_edbd66a372f185dad19d92c92abeea7c.csv
BOQ
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .